RU2620066C2 - Композиции и способы профилактики или лечения заболеваний, состояний или процессов, характеризуемых аберрантной пролиферацией фибробластов и отложением внеклеточного матрикса - Google Patents

Композиции и способы профилактики или лечения заболеваний, состояний или процессов, характеризуемых аберрантной пролиферацией фибробластов и отложением внеклеточного матрикса Download PDF

Info

Publication number
RU2620066C2
RU2620066C2 RU2013150249A RU2013150249A RU2620066C2 RU 2620066 C2 RU2620066 C2 RU 2620066C2 RU 2013150249 A RU2013150249 A RU 2013150249A RU 2013150249 A RU2013150249 A RU 2013150249A RU 2620066 C2 RU2620066 C2 RU 2620066C2
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
kinase
seq
polypeptide
another embodiment
Prior art date
Application number
RU2013150249A
Other languages
English (en)
Russian (ru)
Other versions
RU2013150249A (ru
Inventor
Синтия ЛЭНДЕР
Колин БРОФИ
Original Assignee
Мори Матрикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мори Матрикс, Инк. filed Critical Мори Матрикс, Инк.
Publication of RU2013150249A publication Critical patent/RU2013150249A/ru
Application granted granted Critical
Publication of RU2620066C2 publication Critical patent/RU2620066C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
RU2013150249A 2011-04-12 2012-04-12 Композиции и способы профилактики или лечения заболеваний, состояний или процессов, характеризуемых аберрантной пролиферацией фибробластов и отложением внеклеточного матрикса RU2620066C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161474370P 2011-04-12 2011-04-12
US61/474,370 2011-04-12
PCT/US2012/033368 WO2012142320A2 (en) 2011-04-12 2012-04-12 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Publications (2)

Publication Number Publication Date
RU2013150249A RU2013150249A (ru) 2015-05-20
RU2620066C2 true RU2620066C2 (ru) 2017-05-22

Family

ID=47006527

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013150249A RU2620066C2 (ru) 2011-04-12 2012-04-12 Композиции и способы профилактики или лечения заболеваний, состояний или процессов, характеризуемых аберрантной пролиферацией фибробластов и отложением внеклеточного матрикса

Country Status (15)

Country Link
US (2) US9642888B2 (enExample)
EP (1) EP2696888B1 (enExample)
JP (1) JP6031510B2 (enExample)
KR (1) KR101862291B1 (enExample)
CN (3) CN104302310A (enExample)
AU (1) AU2012242768B2 (enExample)
BR (1) BR112013026313A8 (enExample)
CA (2) CA2832910C (enExample)
DK (1) DK2696888T3 (enExample)
ES (1) ES2711670T3 (enExample)
HK (1) HK1255005A1 (enExample)
MX (1) MX359516B (enExample)
RU (1) RU2620066C2 (enExample)
SG (2) SG194135A1 (enExample)
WO (1) WO2012142320A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2790189C1 (ru) * 2022-03-22 2023-02-15 Зулета Зауалевна Хапсирокова Способ лечения хронического рецидивирующего афтозного стоматита

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1976828T3 (pl) 2005-12-29 2017-07-31 Celtaxsys, Inc. Pochodne diaminy jako inhibitory hydrolazy leukotrienu a4
US8741849B2 (en) 2007-01-10 2014-06-03 Purdue Research Foundation Kinase inhibitors and uses thereof
EP2155228B1 (en) 2007-01-10 2014-04-02 Purdue Research Foundation Polypeptide inhibitors of hsp27 kinase and uses therefor
EP2378875B1 (en) * 2008-12-10 2018-05-30 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
WO2011017132A2 (en) * 2009-07-27 2011-02-10 Purdue Research, Foundation Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
EP2575855A4 (en) * 2010-05-24 2014-03-12 Moerae Matrix Inc METHOD FOR TREATING OR PREVENTING VASCULAR GRAFT BREAKAGE
US9890200B2 (en) * 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
EP2696888B1 (en) 2011-04-12 2018-12-05 Moerae Matrix, Inc., Compositions and methods for preventing or treating pulmonary fibrosis
FR2976587B1 (fr) * 2011-06-20 2015-04-03 Basf Beauty Care Solutions F Methode de dosage in vitro par technique immunologique
WO2013134636A1 (en) 2012-03-09 2013-09-12 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
CA2884802A1 (en) * 2012-10-31 2014-05-08 Galecto Biotech Ab Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
JP6527851B2 (ja) 2013-03-12 2019-06-05 セルタクシス，インコーポレイテッド ロイコトリエンａ４加水分解酵素を阻害する方法
EP2968264A4 (en) 2013-03-14 2016-11-02 Celtaxsys Inc INHIBITORS OF LEUCOTRIENE A4 HYDROLASE
CA2910766C (en) 2013-04-30 2020-12-15 Otitopic Inc. Dry powder formulations and methods of use
WO2015138784A2 (en) * 2014-03-14 2015-09-17 Moerae Matrix, Inc. Compositions and methods for preventing or treating chronic lung allograft dysfunction (clad) and idiopathic pulmonary fibrosis (ipf)
US10336788B2 (en) * 2014-04-17 2019-07-02 Moerae Matrix, Inc. Inhibition of cardiac fibrosis in myocardial infarction
KR20170083063A (ko) * 2014-11-17 2017-07-17 모레 매트릭스 인코포레이티드 이상 섬유모세포 증식 및 세포외 기질 침착을 특징으로 하는 질병, 질환, 또는 과정의 예방 또는 치료용 조성물 및 방법
BR112017014737A2 (pt) 2015-01-08 2018-01-16 Moerae Matrix Inc formulação de peptídeos inibidores de mk2
CN107921082A (zh) * 2015-03-12 2018-04-17 莫伊莱麦屈克斯公司 含有mk2抑制剂肽的组合物用于治疗非小细胞肺癌的用途
CA3076353A1 (en) 2017-09-22 2019-03-28 Otitopic Inc. Dry powder compositions with magnesium stearate
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
CN107987128B (zh) * 2017-11-17 2019-06-11 广东医科大学 一种功能多肽及其在制备防治肺纤维化药物中的应用
JP7471660B2 (ja) 2018-05-17 2024-04-22 アクチュエイト セラピューティクス インク． グリコーゲンシンターゼキナーゼ３型β阻害剤による特発性肺線維症の治療
CA3102077A1 (en) 2018-05-31 2019-12-05 Sanjeev AHUJA Method of reducing pulmonary exacerbations in respiratory disease patients
CN110108883A (zh) * 2018-10-27 2019-08-09 广州呼吸健康研究院 用于筛选与靶治疗ards患者的msc精准医学的标志物组合
CN109406795A (zh) * 2018-11-20 2019-03-01 昆明医科大学 一种轻型脑外伤的血清分子诊断标记物及应用
WO2021040673A1 (en) * 2019-08-26 2021-03-04 Alain Martin Methods for the treatment of chronic hypoxemia and inhibiting lung fibrosis in patients with pulmonary fibrosis with and without copd
USD958124S1 (en) 2019-12-16 2022-07-19 Samsung Electronics Co., Ltd. Television receiver
USD978094S1 (en) 2019-12-27 2023-02-14 Samsung Electronics Co., Ltd. Television receiver
WO2021146662A1 (en) * 2020-01-17 2021-07-22 Muhammed Majeed Therapeutic compositions and methods for pulmonary fibrosis
CN112386682B (zh) * 2020-02-12 2022-12-06 王斌 纤连蛋白在制备治疗新型冠状病毒肺炎药物中的应用
US20230127499A1 (en) * 2020-03-30 2023-04-27 Figene, Llc Peptides and adjuvants for augmentation of fibroblast therapy for coronavirus
EP4142751A4 (en) * 2020-04-01 2025-01-08 Figene, LLC Fibroblast mediated expansion and augmentation of immune regulatory cells for treatment of acute respiratory distress syndrome (ards)
US11505584B2 (en) * 2020-04-21 2022-11-22 Remodeless Cv Ltd Therapy for reducing brain damage
USD989726S1 (en) 2020-12-03 2023-06-20 Samsung Electronics Co., Ltd. Television receiver
AU2021390125A1 (en) * 2020-12-03 2023-06-22 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising anti-connective tissue growth factor antibody
USD989017S1 (en) 2020-12-03 2023-06-13 Samsung Electronics Co., Ltd. Television receiver
US20220202852A1 (en) * 2020-12-30 2022-06-30 Briotech, Inc. Methods and compositions of aqueous hypobromous acid for the treatment and prevention of inflammatory conditions
WO2022204045A1 (en) * 2021-03-22 2022-09-29 Spiritus Therapeutics, Inc. Diagnostic and therapeutic uses of purified potent exosomes containing disease-based and therapy based signature cargo
CN113440431A (zh) * 2021-08-02 2021-09-28 山西锦波生物医药股份有限公司 重组ⅲ型人源化胶原蛋白在头皮护理中的用途及包含其的头皮护理产品
CN116262112A (zh) * 2021-12-14 2023-06-16 南京安吉生物科技有限公司 一种雾化吸入用融合多肽制剂及其制备方法和应用
KR20240134978A (ko) 2022-01-14 2024-09-10 상하이 한서 바이오메디컬 컴퍼니 리미티드 피리딘 함유 폴리시클릭 유도체, 이의 제조 방법 및 용도
CN114522221B (zh) * 2022-02-28 2024-04-19 中国人民解放军陆军特色医学中心 分泌蛋白ctgf在用于制备治疗急性肺损伤药物中的应用
WO2023178169A2 (en) * 2022-03-15 2023-09-21 Anemoi Biotech Holdings, Inc. Compositions and methods for treating the pathophysiology of severe viral infection
CN116421704A (zh) * 2023-02-20 2023-07-14 成都佩德生物医药有限公司 多肽pd-dp-005在制备治疗肺部疾病药物中的应用及其药物
CN116789751B (zh) * 2023-08-22 2023-11-17 中国农业大学 预防和/或治疗纤维化疾病的多肽及其应用
CN117577330B (zh) * 2024-01-15 2024-04-02 北京大学 预测非酒精性脂肪性肝病肝纤维化程度的装置及存储介质

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2387281C2 (ru) * 2003-11-25 2010-04-27 Хилл`С Пет Ньютришн, Инк. Композиция для потребления животными и способ снижения активности мар-киназы

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
ES286422Y (es) 1982-10-08 1986-09-16 Glaxo Group Limited Dispositivo para administrar medicamentos a pacientes
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
PT83094B (pt) 1985-07-30 1993-07-30 Glaxo Group Ltd Dispositivos proprios para a administracao de medicamentos a pacientes
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
DE69333955D1 (de) 1992-04-24 2006-02-02 Stanford Res Inst Int Targeting homologer sequenzen in eukaryotenzellen
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
PT733059E (pt) 1993-12-09 2001-03-30 Univ Jefferson Compostos e metodos para mutacoes dirigidas ao local em celulas eucarioticas
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
ES2261195T3 (es) 1999-04-05 2006-11-16 Mannkind Corporation Metodo de formacion de particulas finas.
ES2395096T3 (es) 1999-06-29 2013-02-08 Mannkind Corporation Purificación y estabilización de agentes farmacéuticos a base de péptidos y proteínas
KR20110017465A (ko) * 2002-04-25 2011-02-21 더 스크립스 리서치 인스티튜트 폐질환 증상의 치료 및 예방
AR040603A1 (es) * 2002-07-19 2005-04-13 Abbott Lab S A El uso de un anticuerpo anti-tnfalfa neutralizador de alta afinidad en la fabricacion de un medicamento y conjunto de elementos
WO2005110410A2 (en) * 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
JP2008510825A (ja) 2004-08-23 2008-04-10 マンカインド コーポレイション ホスホジエステラーゼ５型の阻害剤の肺送達
CN101227918A (zh) * 2005-04-29 2008-07-23 加州大学评议会 治疗以炎症反应为特征的病理的肽和肽模拟物
KR101486397B1 (ko) 2005-09-14 2015-01-28 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
KR20080096809A (ko) 2006-02-22 2008-11-03 맨카인드 코포레이션 디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
JP2009532489A (ja) * 2006-04-03 2009-09-10 テバ ファーマシューティカル インダストリーズ リミティド 薬剤微粒子
US8741849B2 (en) 2007-01-10 2014-06-03 Purdue Research Foundation Kinase inhibitors and uses thereof
EP2155228B1 (en) 2007-01-10 2014-04-02 Purdue Research Foundation Polypeptide inhibitors of hsp27 kinase and uses therefor
WO2008098096A1 (en) * 2007-02-08 2008-08-14 Boehringer Ingelheim International Gmbh Anti-cytokine heterocyclic compounds
US20080282320A1 (en) 2007-05-11 2008-11-13 Denovo Andrew Security Compliance Methodology and Tool
US20110017340A1 (en) 2007-12-21 2011-01-27 Cabot Corporation Syntactic Foam Compositions, Pipelines Insulated with Same, and Method
DK2349310T3 (da) 2008-10-20 2014-08-11 Moerae Matrix Inc Polypeptid til behandling eller forebyggelse af adhæsioner
EP2378875B1 (en) 2008-12-10 2018-05-30 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
EP2575855A4 (en) * 2010-05-24 2014-03-12 Moerae Matrix Inc METHOD FOR TREATING OR PREVENTING VASCULAR GRAFT BREAKAGE
EP2696888B1 (en) 2011-04-12 2018-12-05 Moerae Matrix, Inc., Compositions and methods for preventing or treating pulmonary fibrosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2387281C2 (ru) * 2003-11-25 2010-04-27 Хилл`С Пет Ньютришн, Инк. Композиция для потребления животными и способ снижения активности мар-киназы

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FRANKEL A.E. et al., Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor, Protein Eng., 2000, v.13, is.8, p.575-581. *
LAUREN M.K., Inhibition of Lipopolysaccharide-Stimulated Chronic Obstructive Pulmonary Disease Macrophage Inflammatory Gene Expression by Dexamethasone and the p38 Mitogen-Activated Protein Kinase Inhibitor N-cyano-N-(2-{ [8-(2,6-difluorophenyl)-4- (4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidin-2-yl]amino} ethyl)guanidine (SB706504), The J. of pharm. and exp. therapeutics, 2009, v.328, is.2, p.458-468. *
PAKULA A.A. et al., Genetic analysis of protein stability and function, Ann. Rev. Genet., 1989, v.23, p.289-310. *
PAKULA A.A. et al., Genetic analysis of protein stability and function, Ann. Rev. Genet., 1989, v.23, p.289-310. FRANKEL A.E. et al., Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor, Protein Eng., 2000, v.13, is.8, p.575-581. *
SOUSA A.M., Smooth Muscle α-Actin Expression and Myofibroblast Differentiation by TGFβ are Dependent Upon MK2, J. Cell Biochem., 2007, v.100, is.6, p.1581-1592. *
SOUSA A.M., Smooth Muscle α-Actin Expression and Myofibroblast Differentiation by TGFβ are Dependent Upon MK2, J. Cell Biochem., 2007, v.100, is.6, p.1581-1592. LAUREN M.K., Inhibition of Lipopolysaccharide-Stimulated Chronic Obstructive Pulmonary Disease Macrophage Inflammatory Gene Expression by Dexamethasone and the p38 Mitogen-Activated Protein Kinase Inhibitor N-cyano-N-(2-{ [8-(2,6-difluorophenyl)-4- (4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidin-2-yl]amino} ethyl)guanidine (SB706504), The J. of pharm. and exp. therapeutics, 2009, v.328, is.2, p.458-468. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2830698C1 (ru) * 2020-01-23 2024-11-25 Шанхай Синвида Биотекнолоджи Ко. Лтд. Соответствующая мишень для лечения фиброзирующих заболеваний и ее применение
RU2790189C1 (ru) * 2022-03-22 2023-02-15 Зулета Зауалевна Хапсирокова Способ лечения хронического рецидивирующего афтозного стоматита

Also Published As

Publication number Publication date
CN111110850A (zh) 2020-05-08
DK2696888T3 (en) 2019-03-25
US9642888B2 (en) 2017-05-09
CN108014340A (zh) 2018-05-11
BR112013026313A2 (pt) 2016-12-27
CA3042808A1 (en) 2012-10-18
KR101862291B1 (ko) 2018-05-29
WO2012142320A2 (en) 2012-10-18
CN104302310A (zh) 2015-01-21
WO2012142320A3 (en) 2015-06-11
SG194135A1 (en) 2013-11-29
CA2832910A1 (en) 2012-10-18
AU2012242768A1 (en) 2013-10-24
ES2711670T3 (es) 2019-05-06
CA2832910C (en) 2019-07-02
RU2013150249A (ru) 2015-05-20
EP2696888A4 (en) 2016-04-20
KR20140063517A (ko) 2014-05-27
US20190022169A1 (en) 2019-01-24
WO2012142320A8 (en) 2014-02-20
AU2012242768B2 (en) 2017-10-12
JP2014533235A (ja) 2014-12-11
EP2696888A2 (en) 2014-02-19
SG10201604560TA (en) 2016-07-28
JP6031510B2 (ja) 2016-11-24
MX2013011771A (es) 2014-07-30
NZ616672A (en) 2016-04-29
MX359516B (es) 2018-10-01
BR112013026313A8 (pt) 2018-01-30
EP2696888B1 (en) 2018-12-05
HK1255005A1 (zh) 2019-08-02
US20120263680A1 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
RU2620066C2 (ru) Композиции и способы профилактики или лечения заболеваний, состояний или процессов, характеризуемых аберрантной пролиферацией фибробластов и отложением внеклеточного матрикса
WO2016081475A1 (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
US10562947B2 (en) Compositions and methods for preventing or treating diseases, conditions or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
JP6655547B2 (ja) 慢性肺移植片機能不全（ｃｌａｄ）および特発性肺線維症（ｉｐｆ）を予防または処置するための組成物および方法
NZ616672B2 (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
HK1194983B (en) Compositions and methods for preventing or treating pulmonary fibrosis

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200413